Firalis-initiated public-private consortium project, SAFE-T,has been approved for a major European funding. The SAFE-T Project aims to qualify Translational Safety Biomarkers in clinics. It is the highest budget financed among the 18 first calls launched in 2008 by the Innovative Medicines Initiative-Joint Undertaking (IMI-JU). Firalis created the SAFE-T (Safer And Faster Evidence-based Translation) Applicant Consortium…Read more
Duis ultrices purus tortor! Maecenas semper magna at risus rhoncus euismod. Fusce fringilla, quam et dictum vestibulum, nunc sapien imperdiet odio, et convallis lorem augue vitae sem. Vestibulum mattis orci a est bibendum mollis. Ut varius felis nec lectus tinci auctor quam hendrerit odio placerat tempor. Phasellus diam quam, auctor vel blandit vel; tristique id lectus. Nam consequat leo hendrerit mi posuere nec vulputate mauris sagittis. Aenean porttitor metus vitae dui fermentum posuere.
Recent Posts by admin
OSEO Alsace announced a further innovation support for Firalis, as it entered into the final stage with the IMI-JU project on translational safety biomarkers.Read more
Firalis servicing team analyses Complex x-omics data, and interprets them with regard to basic science and to the clinical relevance. Firalis is also pleased to contribute to the publication of such x-omics data. Improved xenogenic hepatocyte implantation into nude mouse liver parenchyma with acute liver failure when followed by repeated anti-Fas antibody (Jo2) treatment. Isabelle…Read more
Firalis has created and coordinates a European applicant consortium that will develop a generic qualification process for candidate translational safety biomarkers in the frame of IMI Joint Undertaking.Read more
Recent Comments by admin
No comments by admin yet.